Calendar Opportunities Companies Compare Analytics Learn Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar with AI-powered predictions. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Real-time alerts for biotech investors.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Biotech Glossary
Embed Widget

Legal

About
ML Track Record
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

⚠️ Not Financial Advice (NFA)

CatalystAlert provides data aggregation and analysis tools only. All probability scores and predictions are based on historical data and are NOT guarantees of future results. Past performance does not indicate future success. We are not responsible for the accuracy of third-party data sources. Always consult a qualified financial advisor before making investment decisions.

© 2025 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

REC-4881 - Phase 2 | RXRX Pipeline | CatalystAlert

REC-4881

Phase 2

Recursion Pharmaceuticals, Inc. (RXRX)

16%

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

Jul 2026~

RXRXPhase 2

REC-4881 Phase 2 Results Expected

REC-4881 • AXIN1 Gene Mutation

Drug Information

Target Indication

AXIN1 Gene Mutation

Clinical Trial

Last updated: 12/4/2025

Developer

RXRX

Recursion Pharmaceuticals, Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

GTAEXS617Phase 2

Advanced Solid Tumor

Familial Adenomatous Polyposis

Cerebral Cavernous Malformation

REC-1245Phase 2

Unresectable

View full pipeline